Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy

SIMPLE SUMMARY: Hepatocellular carcinoma (HCC) is a major cause of cancer death worldwide. Due to its high recurrence rate, many HCC patients progress to an advanced stage and require systemic therapy. Among six available chemotherapy regimens for advanced HCC, atezolizumab/bevacizumab (Atezo/Bev) c...

Descripción completa

Detalles Bibliográficos
Autores principales: Myojin, Yuta, Kodama, Takahiro, Sakamori, Ryotaro, Maesaka, Kazuki, Matsumae, Takayuki, Sawai, Yoshiyuki, Imai, Yasuharu, Ohkawa, Kazuyoshi, Miyazaki, Masanori, Tanaka, Satoshi, Mita, Eiji, Tawara, Seiichi, Yakushijin, Takayuki, Nozaki, Yasutoshi, Hagiwara, Hideki, Tahata, Yuki, Yamada, Ryoko, Hikita, Hayato, Tatsumi, Tomohide, Takehara, Tetsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870238/
https://www.ncbi.nlm.nih.gov/pubmed/35205631
http://dx.doi.org/10.3390/cancers14040883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870238/
https://www.ncbi.nlm.nih.gov/pubmed/35205631
http://dx.doi.org/10.3390/cancers14040883

Ejemplares similares